Thermo-Responsive Ocular Hydrogel Microspheres for Extended Anti-VEGF Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery systems for treating choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) involve frequent intravitreal injections, which can lead to complications and require a reduction in frequency to minimize risks.
Innovation Solution
A biodegradable microsphere-hydrogel composition that includes thermo-responsive microcapsules to control the release of treatment agents like anti-VEGF, using components such as PLGA, Mg(OH)2, and BSA, which change state at body temperature to provide extended and controlled drug release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If frequent intravitreal injections are administered to maintain therapeutic efficacy, then treatment effectiveness is improved, but risk of complications increases
Solution Approach 1:
The patent applies preliminary action by pre-encapsulating anti-VEGF therapeutics in biodegradable microspheres that are suspended in a hydrogel matrix before injection. This allows the drug to be delivered in a controlled-release format from the first administration, eliminating the need for frequent repeat injections and thereby reducing injection-related complications while maintaining therapeutic efficacy.
Solution Approach 2:
The patent uses a hydrogel matrix as an intermediary carrier that suspends and controls the release of drug-loaded microspheres. This intermediary system enables sustained drug delivery over time, reducing the frequency of direct injections into the eye and thereby minimizing injection-related complications while ensuring continuous therapeutic effect.
2Device complexity
If microcapsules are injected into the eye as independent units, then delivery system simplicity is improved, but risk of lodging in ocular tissues increases
Solution Approach 1:
The patent merges multiple microspheres containing drug payloads into a single hydrogel matrix structure. This combination approach allows the microspheres to be delivered together as a unified system rather than as independent units, reducing the risk of individual microspheres lodging in ocular tissues while maintaining the simplicity of the overall delivery system.
Solution Approach 2:
The patent creates a composite material system where biodegradable microspheres are embedded within a hydrogel matrix. This composite structure combines the drug-delivery capability of microspheres with the tissue-compatible, gel-forming properties of hydrogel, preventing microsphere lodging while enabling controlled drug release.
3Reliability
If release rate is increased to improve treatment effectiveness, then therapeutic efficacy is improved, but duration of action decreases
Solution Approach 1:
The patent applies dynamics by designing a two-stage release system where the hydrogel matrix provides initial drug release and the embedded microspheres provide sustained release over an extended period. This dynamic release profile ensures high initial therapeutic efficacy while maintaining drug delivery over months, resolving the contradiction between release rate and duration of action.
Solution Approach 2:
The patent ensures continuity of useful action by creating a sustained-release system where the hydrogel-microsphere composite continuously delivers anti-VEGF therapeutic over an extended period (months). This continuous delivery maintains therapeutic efficacy without requiring frequent re-dosing, thereby achieving both high effectiveness and long duration of action.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system reduces the frequency of injections, minimizes complications, and maintains therapeutic efficacy for up to 6 months, allowing for safer and more effective treatment of CNV.
Implementation Method 1
The hydrogel is thermo-responsive in that it desirably changes its physical state from a liquid-like state at room temperature to a more solid state at body temperature (e.g., at a physiological temperature of about 32° C. to about 37° C.).
Implementation Method 2
The rate of release can be controlled via the rate of degradation, which can be controlled, for example, by the components of the microcapsules
Data Source
AI summary
A hydrogel delivery composition and method, including degradable microcapsules suspended in a degradable thermo-responsive hydrogel. The hydrogel is thermo-responsive at a physiological temperature and changes after application to a more solid state due to body temperatures. The composition includes one or more treatment agents to be released over time as the composition degrades. The composition can be varied to modify the structure and/or release of the treatment agent. The degradable microcapsules include one or more of magnesium hydroxide (Mg(OH)2), bovine serum albumin (BSA), polyethylene glycol (PEG), and sucrose to improve release duration.